These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 21185787)

  • 1. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
    Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
    Osada T; Morse MA; Lyerly HK; Clay TM
    Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
    Nicol AJ; Tazbirkova A; Nieda M
    Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer.
    Kurosaki M; Horiguchi S; Yamasaki K; Uchida Y; Motohashi S; Nakayama T; Sugimoto A; Okamoto Y
    Cancer Immunol Immunother; 2011 Feb; 60(2):207-15. PubMed ID: 20978887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
    Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
    Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
    Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
    J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
    Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
    J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.